Trials / Completed
CompletedNCT06422013
Clinical Study to Evaluate the Body Fat Reducing Effect and Safety of GTB1
A Randomized, Double-blind, Placebo-controlled, Parallel-design Clinical Study to Evaluate the Body Fat Reducing Effect and Safety of Lactiplantibacillus Plantarum APsulloc 331261(GTB1)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Amorepacific Corporation · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study was conducted to investigate the effects of daily supplementation of GTB1 on decrease of body fat.
Detailed description
This study was a 12 week, randomized, double-blind, placebo-controlled human trial. 100 subjects were randomly divided into GTB1 group and placebo group. It is to evaluate the changes in the displayed evaluation items when taking GTB1 once a day, in comparison with taking a placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | GTB1 | oral administration of GTB1 powder packet once daily |
| DIETARY_SUPPLEMENT | Placebo | oral administration of placebo powder packet once daily |
Timeline
- Start date
- 2022-10-28
- Primary completion
- 2023-12-08
- Completion
- 2023-12-08
- First posted
- 2024-05-20
- Last updated
- 2024-05-22
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06422013. Inclusion in this directory is not an endorsement.